Open Science Research Package: A Candidate Auxiliary Conditioning System for Late‑Stage Liver Disease, v1.0
This open science package documents a candidate auxiliary conditioning formulation and process workflow for late‑stage liver disease research. It includes reference formulation ratios, pretreatment protocols, quality control frameworks, safety evaluation considerations, and an anti‑monopolization public licensing framework. This package is for academic and open‑science reference only. It is not an approved pharmaceutical product, not a clinical treatment guarantee, and cannot substitute standard medical care. All experimental validation, clinical trials and regulatory approvals must be independently completed by qualified institutions. This public release provides a timestamped, hash‑verified record for prior‑art preservation under open science principles, to prevent unlawful hijacking of the disclosed technical scheme via exclusive patenting. No claim of cure or guaranteed therapeutic efficacy is made. ## Limitations of this research package This is only an open‑science research deposit, NOT a finished pharmaceutical product, and has NOT completed large‑scale human clinical trials. 1. No guaranteed therapeutic efficacy. The formulation is built based on published in‑vitro and animal‑derived bioactivity of individual raw materials. There is no conclusive clinical evidence confirming therapeutic benefit for human late‑stage liver disease. It is not designed for direct tumour‑killing or curing cancer. 2. Safety risks remain. Some components may exert effects on blood‑coagulation and liver metabolism. Any human‑related testing must obtain formal ethical‑committee approval and be supervised by licensed medical practitioners. Self‑preparation and self‑medication are strongly discouraged. 3. Prior‑art defensive boundary. This deposit can serve as prior‑art evidence against patent applications filed AFTER the publication date (2026‑11‑19). It cannot invalidate patent applications submitted before this release date. Substantial new modifications to formulation, extraction process or dosage‑form may generate new technical solutions outside the scope of this deposit. 4. Licence enforcement limits. The supplementary anti‑monopoly public licence relies on public archival evidence and community reputation. It does not possess automatic cross‑border judicial enforcement power. 5. Regulatory note. Obtaining this research package does NOT equal marketing‑approval. Any commercial pharmaceutical‑listing must independently finish toxicology studies, pre‑clinical research, clinical trials, ethical review and official regulatory registration together with GMP‑compliant manufacturing. ------------------------------------------------------------------------------- ## 补充:研究局限性与反垄断郑重声明 1. 本文件仅为开放科学预临床研究包,**不是已经验证有效的肝癌治疗药品**。本配方全部为食材、药食同源原料;文档仅参考公开已上市肝癌药物的病理作用机理作为设计思路,全文不包含任何化学抗癌药物实物、配比与合成工艺。没有完成毒理、动物药效、大规模人体临床试验,不保证对晚期肝细胞癌具备治疗、缩小肿瘤、治愈的效果;直接抗肿瘤潜力低于2.5分(满分10分)。 2. 安全风险提示:配方部分组分存在凝血影响、肝脏代谢负荷风险。晚期肝细胞癌属于危重疾病,严禁个人自行抓取原料煎煮当作药物服用。所有人体试验,必须经过伦理委员会批准,在执业医师全程监督下开展。若与靶向、免疫等抗肿瘤标准药物联合研究,还必须评估食材‑药物相互作用风险。 3. 🚫**反垄断郑重约定** 本技术包通过Zenodo公开存证生成带时间戳、哈希校验的永久公开记录。 **禁止任何个人、任何药厂、任何商业机构,针对本套完整公开的配方、预处理工艺、提取复配流程、质控体系申请独占专利、排他专利、买断技术,实现商业垄断。** ① 凡是在本包Zenodo公开发布日之后,原样照搬本套完整技术方案提交的专利申请,本存证将作为现有技术证据用于抗辩、驳回、专利无效。 ② 任何基于本包做出的改良、衍生版本,必须完全沿用本套《公益反独占开源许可协议v1.1》完整公开,不允许将衍生成果私有化锁闭、独占牟利。 ③ 即便机构投入资金完成毒理、临床、药监注册拿到上市资质,也不允许通过专利、协议手段独占封锁本原始公开技术;商用量产必须遵守极低公益费率、最高公益限价、预留贫困人群免费/补贴产能配额的约束。 4. 证据边界:本存证仅对抗**发布日期之后提交的相同完整方案专利申请**;无法推翻发布时间之前已经递交的专利。如果他人对配方、工艺做出实质性大幅度创新改动,改动后全新的技术方案不在本存证防御覆盖范围内。 5. 许可执行说明:本公益反独占许可依靠Zenodo公开DOI‑哈希证据链、科研社区公信力、违约行为公开公示形成约束,不具备自动跨境司法强制执行力。 6. 监管提示:获取本研究文档不等于药品上市许可。任何想要将本组合物商业化做成制剂上市,必须独立完成全套毒理试验、预临床、人体临床试验、伦理审查、各国药监注册以及符合GMP规范生产。 > 只要下载、阅读、复制、使用、改良本技术包全部或部分内容,即代表完全接受本反垄断声明与《公益反独占开源许可协议 v1.1》全部条款。
Authors
- Hsiao Ling Liew
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24362705
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00